NIP
TRML

Nicholas Investment Partners’s Tourmaline Bio TRML Stock Holding History

Nicholas Investment Partners’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,250
Closed -$221K – 206
2022
Q1 		$221K Buy
+2,250
New +$211K 0.02% 189

Other funds holding TRML

Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Nicholas Investment Partners's TRML Position: Q2 2022 in Review

Nicholas Investment Partners sold out of Tourmaline Bio (TRML) in Q2 2022, closing a stake of 2,250 shares — an estimated $221K sold.

Nicholas Investment Partners first reported a position in TRML in Q1 2022 and held it in 1 quarter. The position peaked at $221K in Q1 2022. 59 funds tracked by Wall St. Rank hold TRML as of Q2 2022.

  • Nicholas Investment Partners reported no remaining Tourmaline Bio position as of Q2 2022 after selling out during the quarter.
  • Nicholas Investment Partners sold 2,250 Tourmaline Bio shares in Q2 2022, an estimated $221K.
  • Nicholas Investment Partners first reported a position in Tourmaline Bio in Q1 2022 and held it in 1 quarter.
  • Nicholas Investment Partners's Tourmaline Bio position peaked at $221K in Q1 2022.
  • 59 funds tracked by Wall St. Rank held Tourmaline Bio as of Q2 2022.

Based on Nicholas Investment Partners's 13F filing for Q2 2022, filed 10 Aug 2022.